Skip to main content
. 2015 Apr 28;54(10):1043–1055. doi: 10.1007/s40262-015-0271-5

Fig. 2.

Fig. 2

Dose-proportionality assessment of enzalutamide for doses ranging from 30 to 360 mg/day. A linear regression (power model) analysis was applied to the mean values for the AUCτ after approximately 3 months of treatment. Circles denote individual patients and the gray area depicts 90 % CIs. AUC τ area under the plasma concentration–time curve during one 24-h dose interval at steady state, CIs confidence intervals